BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 28885219)

  • 1. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
    Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
    Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.
    Miller CD; El-Kholi R; Faragon JJ; Lodise TP
    Pharmacotherapy; 2007 Oct; 27(10):1379-86. PubMed ID: 17896893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    J Clin Pharm Ther; 2008 Aug; 33(4):393-400. PubMed ID: 18613857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
    Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
    HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy.
    Yiu P; Nguyen NN; Holodniy M
    Pharmacotherapy; 2011 May; 31(5):480-9. PubMed ID: 21923429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.
    Farhoudi M; Khalili H; Karimzadeh I; Abbasian L
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):471-9. PubMed ID: 25557864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.
    Jakeman B; Nasiri M; Ruth L; Morse C; Mahatme S; Patel N
    Ann Pharmacother; 2017 May; 51(5):365-372. PubMed ID: 28367698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of comedications and potential drug-drug interactions in people living with HIV in China.
    Chen R; Chen J; Tang Q; Meng Z; Luo L; Zhang W; Deng A; Zhang L; Wang J; Qi T; Zhang R; Shen Y; Liu L; Steinhart C; Lu H
    J Infect Chemother; 2020 Jul; 26(7):722-728. PubMed ID: 32354599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy.
    Rajesh R; Vidyasagar S; Varma DM; Mohiuddin S; Noorunnisa
    Int J Risk Saf Med; 2011; 23(3):171-80. PubMed ID: 22020397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Significant Drug-Drug Interaction in a Large Antiretroviral Treatment Centre in Lagos, Nigeria.
    Oreagba IA; Usman SO; Oshikoya KA; Akinyede A; Agbaje E; Opanuga O; Akanmu S
    J Popul Ther Clin Pharmacol; 2019 Jan; 26(1):e1-e19. PubMed ID: 31002484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.
    Kigen G; Kimaiyo S; Nyandiko W; Faragher B; Sang E; Jakait B; Owen A; Back D; Gibbons S; Seden K; Khoo SH;
    PLoS One; 2011 Feb; 6(2):e16800. PubMed ID: 21373194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.
    Oshikoya KA; Oreagba IA; Lawal S; Awodele O; Ogunleye OO; Senbanjo IO; Olayemi SO; Ezeaka VC; Temiye EO; Adeyemo TA; Opanuga O; Lesi OA; Akanmu SA
    HIV AIDS (Auckl); 2014; 6():49-59. PubMed ID: 24741328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically significant drug interactions between antiretroviral and co-prescribed drugs in HIV infected patients: retrospective cohort study.
    Al Sayed HAH; Sharif-Askari NS; Rahimi MR
    Med Pharm Rep; 2022 Jul; 95(3):260-266. PubMed ID: 36060510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive factors of clinically significant drug-drug interactions among regimens based on protease inhibitors, non-nucleoside reverse transcriptase inhibitors and raltegravir].
    Cervero M; Torres R; Jusdado JJ; Pastor S; Agud JL
    Med Clin (Barc); 2016 Apr; 146(8):339-45. PubMed ID: 26971988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy.
    Peng AT; Huang SH; Lee HY; Wu PY; Kuo HY; Hung CC
    Int J Antimicrob Agents; 2024 Feb; 63(2):107067. PubMed ID: 38141835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunistic infections in relation to antiretroviral status among AIDS patients from south India.
    Srirangaraj S; Venkatesha D
    Indian J Med Microbiol; 2011; 29(4):395-400. PubMed ID: 22120801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.